FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 05/2022”.
The Monitor is a month-to-month printed overview of enterprise capital tendencies within the US-Biotech sector.
As of the top of Might 2022, we establish the next present VC tendencies within the US-Biotech sector:
- In 2022, total Biotech funding within the USA has reached USD 14,106m up to now
- Prime 5 offers exceed USD 230m every, largest transaction amounted to USD 3,000m in Altos Labs
- Catalio Capital Administration (USA) is main the Prime 5 Traders (by deal quantity), adopted by OrbiMed (USA) and Flagship Pioneering (USA)
- Oncology dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink